Method of isolating quaternary phenanthroindolizidine alkaloids with G-quaduplex DNA binding activity from Tylophra atrofolliculata, compositions comprising them and their medical use
US10278966B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 29, 2016 |
| Grant date | May 7, 2019 |
| Priority date | — |
| Expiry date | Apr 29, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K36/27
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of isolating at least one phenanthroindolizidine alkaloid, in particular with telomerase inhibitory activity, from Tylophora atrofolliculata is used to isolate and obtain for example about six to eight phenanthroindolizidine alkaloids, including at least four new phenanthroindolizidine alkaloids which have not been previously isolated. Experimental tests confirmed an exceptional telomerase inhibitory activity of the phenanthroindolizidine alkaloids isolated. A pharmaceutical composition includes at least one phenanthroindolizidine alkaloid and at least one pharmaceutical tolerable excipient. Still further, a method of treating a subject suffering from cancer includes administering at least one phenanthroindolizidine alkaloid isolated from Tylophora atrofolliculata. Also, a method of treating a subject suffering from cancer includes administering to the subject at least one phenanthroindolizidine alkaloid having certain formula.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.